{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,19]],"date-time":"2026-10-19T11:38:58Z","timestamp":1792409938793,"version":"4.4.0"},"reference-count":30,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,7,25]]},"DOI":"10.7759\/cureus.88786","type":"journal-article","created":{"date-parts":[[2025,7,26]],"date-time":"2025-07-26T06:47:33Z","timestamp":1753512453000},"source":"Crossref","is-referenced-by-count":3,"title":["Assessment of Liver Enzymes and the Risk of Non-alcoholic Fatty Liver Disease (NAFLD) Among Information Technology (IT) Professionals"],"prefix":"10.7759","author":[{"given":"Thirumoorthi","family":"Natarajan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shenbaga Lalitha","family":"S","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sujatha","family":"Lakshminarayanan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Balakrishnan","family":"Madhavan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Devi Krishna","family":"Ravichandran","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Krishna","family":"Prasanth","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1002\/hep.28431","article-title":"Global epidemiology of nonalcoholic fatty liver disease-meta-analytic assessment of prevalence, incidence, and outcomes","volume":"64","author":"Younossi ZM","year":"2016","unstructured":"Younossi ZM, Koenig AB, Abdelatif D, Fazel Y, Henry L, Wymer M. Global epidemiology of nonalcoholic fatty liver disease-meta-analytic assessment of prevalence, incidence, and outcomes. Hepatology. 2016, 64:73-84. 10.1002\/hep.28431","journal-title":"Hepatology"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.14218\/JCTH.2017.00013","article-title":"Non-alcoholic fatty liver disease: a clinical update","volume":"5","author":"Pappachan JM","year":"2017","unstructured":"Pappachan JM, Babu S, Krishnan B, Ravindran NC. Non-alcoholic fatty liver disease: a clinical update. J Clin Transl Hepatol. 2017, 5:384-93. 10.14218\/JCTH.2017.00013","journal-title":"J Clin Transl Hepatol"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.3350\/cmh.2022.0424","article-title":"Non-alcoholic fatty liver disease: definition and subtypes","volume":"29","author":"Han SK","year":"2023","unstructured":"Han SK, Baik SK, Kim MY. Non-alcoholic fatty liver disease: definition and subtypes. Clin Mol Hepatol. 2023, 29:S5-S16. 10.3350\/cmh.2022.0424","journal-title":"Clin Mol Hepatol"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1136\/postgradmedj-2018-136316","article-title":"Diagnosis and management of non-alcoholic fatty liver disease","volume":"95","author":"Jennison E","year":"2019","unstructured":"Jennison E, Patel J, Scorletti E, Byrne CD. Diagnosis and management of non-alcoholic fatty liver disease. Postgrad Med J. 2019, 95:314-22. 10.1136\/postgradmedj-2018-136316","journal-title":"Postgrad Med J"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2022.1031633","article-title":"Non-alcoholic fatty liver disease in type 1 diabetes: prevalence and pathophysiology","volume":"13","author":"Memaj P","year":"2022","unstructured":"Memaj P, Jornayvaz FR. Non-alcoholic fatty liver disease in type 1 diabetes: prevalence and pathophysiology. Front Endocrinol (Lausanne). 2022, 13:1031633. 10.3389\/fendo.2022.1031633","journal-title":"Front Endocrinol (Lausanne)"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1007\/s11695-015-1655-1","article-title":"Prevalence and predictors of non-alcoholic fatty liver disease in morbidly obese South Indian patients undergoing bariatric surgery","volume":"25","author":"Praveenraj P","year":"2015","unstructured":"Praveenraj P, Gomes RM, Kumar S, et al.. Prevalence and predictors of non-alcoholic fatty liver disease in morbidly obese South Indian patients undergoing bariatric surgery. Obes Surg. 2015, 25:2078-87. 10.1007\/s11695-015-1655-1","journal-title":"Obes Surg"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1055\/a-0603-7899","article-title":"The relationship between liver enzymes and insulin resistance in type 2 diabetes patients with nonalcoholic fatty liver disease","volume":"50","author":"Sheng X","year":"2018","unstructured":"Sheng X, Che H, Ji Q, et al.. The relationship between liver enzymes and insulin resistance in type 2 diabetes patients with nonalcoholic fatty liver disease. Horm Metab Res. 2018, 50:397-402. 10.1055\/a-0603-7899","journal-title":"Horm Metab Res"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2024.1457598","article-title":"Elevated ALT\/AST ratio as a marker for NAFLD risk and severity: insights from a cross-sectional analysis in the United States","volume":"15","author":"Xuan Y","year":"2024","unstructured":"Xuan Y, Wu D, Zhang Q, Yu Z, Yu J, Zhou D. Elevated ALT\/AST ratio as a marker for NAFLD risk and severity: insights from a cross-sectional analysis in the United States. Front Endocrinol (Lausanne). 2024, 15:1457598. 10.3389\/fendo.2024.1457598","journal-title":"Front Endocrinol (Lausanne)"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.15403\/jgld-293","article-title":"Characterization of patients with biopsy-proven non-alcoholic fatty liver disease and normal aminotransferase levels","volume":"28","author":"Ulasoglu C","year":"2019","unstructured":"Ulasoglu C, Enc FY, Kaya E, Yilmaz Y. Characterization of patients with biopsy-proven non-alcoholic fatty liver disease and normal aminotransferase levels. J Gastrointestin Liver Dis. 2019, 28:427-31. 10.15403\/jgld-293","journal-title":"J Gastrointestin Liver Dis"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.47690","article-title":"Association of screen time usage and physical activity with overweight and obesity among school-going children in Uttar Pradesh","volume":"15","author":"Kaul A","year":"2023","unstructured":"Kaul A, Bansal N, Sharma P, Aneja S, Mahato MP. Association of screen time usage and physical activity with overweight and obesity among school-going children in Uttar Pradesh. Cureus. 2023, 15:e47690. 10.7759\/cureus.47690","journal-title":"Cureus"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0034916","article-title":"Association of sedentary behaviour with metabolic syndrome: a meta-analysis","volume":"7","author":"Edwardson CL","year":"2012","unstructured":"Edwardson CL, Gorely T, Davies MJ, et al.. Association of sedentary behaviour with metabolic syndrome: a meta-analysis. PLoS One. 2012, 7:e34916. 10.1371\/journal.pone.0034916","journal-title":"PLoS One"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.7570\/jomes24005","article-title":"Association between body fat distribution and nonalcoholic fatty liver disease\/fibrosis based on race\/ethnicity","volume":"33","author":"Kim D","year":"2024","unstructured":"Kim D, Cholankeril G, Ahmed A. Association between body fat distribution and nonalcoholic fatty liver disease\/fibrosis based on race\/ethnicity. J Obes Metab Syndr. 2024, 33:326-36. 10.7570\/jomes24005","journal-title":"J Obes Metab Syndr"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.17925\/EE.2020.16.2.152","article-title":"The prevalence and predictors of non-alcoholic fatty liver disease in morbidly obese women - a cross-sectional study from southern India","volume":"16","author":"Atri A","year":"2020","unstructured":"Atri A, Jiwanmall SA, Nandyal MB, et al.. The prevalence and predictors of non-alcoholic fatty liver disease in morbidly obese women - a cross-sectional study from southern India. Eur Endocrinol. 2020, 16:152-5. 10.17925\/EE.2020.16.2.152","journal-title":"Eur Endocrinol"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.4314\/ejhs.v28i1.4","article-title":"Non-alcoholic fatty liver disease and associated factors among type 2 diabetic patients in southwest Ethiopia","volume":"28","author":"Zawdie B","year":"2018","unstructured":"Zawdie B, Tadesse S, Wolide AD, Nigatu TA, Bobasa EM. Non-alcoholic fatty liver disease and associated factors among type 2 diabetic patients in southwest Ethiopia. Ethiop J Health Sci. 2018, 28:19-30. 10.4314\/ejhs.v28i1.4","journal-title":"Ethiop J Health Sci"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.3626","article-title":"Elevated liver enzymes in patients with type 2 diabetes mellitus and non-alcoholic fatty liver disease","volume":"10","author":"Mandal A","year":"2018","unstructured":"Mandal A, Bhattarai B, Kafle P, et al.. Elevated liver enzymes in patients with type 2 diabetes mellitus and non-alcoholic fatty liver disease. Cureus. 2018, 10:e3626. 10.7759\/cureus.3626","journal-title":"Cureus"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1097\/MEG.0000000000002708","article-title":"AST to ALT ratio as a prospective risk predictor for liver cirrhosis in patients with chronic HBV infection","volume":"36","author":"Lai X","year":"2024","unstructured":"Lai X, Chen H, Dong X, et al.. AST to ALT ratio as a prospective risk predictor for liver cirrhosis in patients with chronic HBV infection. Eur J Gastroenterol Hepatol. 2024, 36:338-44. 10.1097\/MEG.0000000000002708","journal-title":"Eur J Gastroenterol Hepatol"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1136\/gut.2006.091454","article-title":"Non-invasive markers associated with liver fibrosis in non-alcoholic fatty liver disease","volume":"55","author":"Guha IN","year":"2006","unstructured":"Guha IN, Parkes J, Roderick PR, Harris S, Rosenberg WM. Non-invasive markers associated with liver fibrosis in non-alcoholic fatty liver disease. Gut. 2006, 55:1650-60. 10.1136\/gut.2006.091454","journal-title":"Gut"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.3389\/fmed.2020.578001","article-title":"Hypoxia and non-alcoholic fatty liver disease","volume":"7","author":"Isaza SC","year":"2020","unstructured":"Isaza SC, Del Pozo-Maroto E, Dom\u00ednguez-Alc\u00f3n L, Elbouayadi L, Gonz\u00e1lez-Rodr\u00edguez \u00c1, Garc\u00eda-Monz\u00f3n C. Hypoxia and non-alcoholic fatty liver disease. Front Med (Lausanne). 2020, 7:578001. 10.3389\/fmed.2020.578001","journal-title":"Front Med (Lausanne)"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2016.04.010","article-title":"Nocturnal hypoxia-induced oxidative stress promotes progression of pediatric non-alcoholic fatty liver disease","volume":"65","author":"Sundaram SS","year":"2016","unstructured":"Sundaram SS, Halbower A, Pan Z, et al.. Nocturnal hypoxia-induced oxidative stress promotes progression of pediatric non-alcoholic fatty liver disease. J Hepatol. 2016, 65:560-9. 10.1016\/j.jhep.2016.04.010","journal-title":"J Hepatol"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2021.647459","article-title":"Long working hours and risk of nonalcoholic fatty liver disease: Korea National Health and Nutrition Examination Survey VII","volume":"12","author":"Song E","year":"2021","unstructured":"Song E, Kim JA, Roh E, et al.. Long working hours and risk of nonalcoholic fatty liver disease: Korea National Health and Nutrition Examination Survey VII. Front Endocrinol (Lausanne). 2021, 12:647459. 10.3389\/fendo.2021.647459","journal-title":"Front Endocrinol (Lausanne)"},{"key":"ref21","doi-asserted-by":"publisher","DOI":"10.18388\/abp.2016_1252","article-title":"Hepatokines and non-alcoholic fatty liver disease","volume":"63","author":"Lebensztejn DM","year":"2016","unstructured":"Lebensztejn DM, Flisiak-Jackiewicz M, Bia\u0142okoz-Kalinowska I, Bobrus-Chociej A, Kowalska I. Hepatokines and non-alcoholic fatty liver disease. Acta Biochim Pol. 2016, 63:459-67. 10.18388\/abp.2016_1252","journal-title":"Acta Biochim Pol"},{"key":"ref22","doi-asserted-by":"publisher","DOI":"10.2337\/dc11-0919","article-title":"Elevated liver function enzymes are related to the development of prediabetes and type 2 diabetes in younger adults: the Bogalusa Heart Study","volume":"34","author":"Nguyen QM","year":"2011","unstructured":"Nguyen QM, Srinivasan SR, Xu JH, Chen W, Hassig S, Rice J, Berenson GS. Elevated liver function enzymes are related to the development of prediabetes and type 2 diabetes in younger adults: the Bogalusa Heart Study. Diabetes Care. 2011, 34:2603-7. 10.2337\/dc11-0919","journal-title":"Diabetes Care"},{"key":"ref23","doi-asserted-by":"publisher","DOI":"10.1002\/hep.29367","article-title":"The diagnosis and management of nonalcoholic fatty liver disease: practice guidance from the American Association for the Study of Liver Diseases","volume":"67","author":"Chalasani N","year":"2018","unstructured":"Chalasani N, Younossi Z, Lavine JE, et al.. The diagnosis and management of nonalcoholic fatty liver disease: practice guidance from the American Association for the Study of Liver Diseases. Hepatology. 2018, 67:328-57. 10.1002\/hep.29367","journal-title":"Hepatology"},{"key":"ref24","doi-asserted-by":"publisher","DOI":"10.1038\/s41575-018-0014-9","article-title":"Noninvasive biomarkers in NAFLD and NASH - current progress and future promise","volume":"15","author":"Wong VW","year":"2018","unstructured":"Wong VW, Adams LA, de L\u00e9dinghen V, Wong GL, Sookoian S. Noninvasive biomarkers in NAFLD and NASH - current progress and future promise. Nat Rev Gastroenterol Hepatol. 2018, 15:461-78. 10.1038\/s41575-018-0014-9","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"ref25","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2017.05.016","article-title":"Treatment of NAFLD with diet, physical activity and exercise","volume":"67","author":"Romero-G\u00f3mez M","year":"2017","unstructured":"Romero-G\u00f3mez M, Zelber-Sagi S, Trenell M. Treatment of NAFLD with diet, physical activity and exercise. J Hepatol. 2017, 67:829-46. 10.1016\/j.jhep.2017.05.016","journal-title":"J Hepatol"},{"key":"ref26","doi-asserted-by":"publisher","DOI":"10.1002\/hep.21262","article-title":"NAFLD in children: a prospective clinical-pathological study and effect of lifestyle advice","volume":"44","author":"Nobili V","year":"2006","unstructured":"Nobili V, Marcellini M, Devito R, et al.. NAFLD in children: a prospective clinical-pathological study and effect of lifestyle advice. Hepatology. 2006, 44:458-65. 10.1002\/hep.21262","journal-title":"Hepatology"},{"key":"ref27","doi-asserted-by":"publisher","DOI":"10.1136\/pgmj.2005.042200","article-title":"Treatment of non-alcoholic fatty liver disease","volume":"82","author":"Adams LA","year":"2006","unstructured":"Adams LA, Angulo P. Treatment of non-alcoholic fatty liver disease. Postgrad Med J. 2006, 82:315-22. 10.1136\/pgmj.2005.042200","journal-title":"Postgrad Med J"},{"key":"ref28","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2019.11.312","article-title":"MAFLD: A consensus-driven proposed nomenclature for metabolic associated fatty liver disease","volume":"158","author":"Eslam M","year":"2020","unstructured":"Eslam M, Sanyal AJ, George J. MAFLD: A consensus-driven proposed nomenclature for metabolic associated fatty liver disease. Gastroenterology. 2020, 158:1999-2014.e1. 10.1053\/j.gastro.2019.11.312","journal-title":"Gastroenterology"},{"key":"ref29","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2028395","article-title":"A placebo-controlled trial of subcutaneous semaglutide in nonalcoholic steatohepatitis","volume":"384","author":"Newsome PN","year":"2021","unstructured":"Newsome PN, Buchholtz K, Cusi K, et al.. A placebo-controlled trial of subcutaneous semaglutide in nonalcoholic steatohepatitis. N Engl J Med. 2021, 384:1113-24. 10.1056\/NEJMoa2028395","journal-title":"N Engl J Med"},{"key":"ref30","doi-asserted-by":"publisher","DOI":"10.1136\/bmjgast-2019-000368","article-title":"Effectiveness of phosphatidylcholine as adjunctive therapy in improving liver function tests in patients with non-alcoholic fatty liver disease and metabolic comorbidities: real-life observational study from Russia","volume":"7","author":"Maev IV","year":"2020","unstructured":"Maev IV, Samsonov AA, Palgova LK, Pavlov CS, Shirokova EN, Vovk EI, Starostin KM. Effectiveness of phosphatidylcholine as adjunctive therapy in improving liver function tests in patients with non-alcoholic fatty liver disease and metabolic comorbidities: real-life observational study from Russia. BMJ Open Gastroenterol. 2020, 7:e000368. 10.1136\/bmjgast-2019-000368","journal-title":"BMJ Open Gastroenterol"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/383576-assessment-of-liver-enzymes-and-the-risk-of-non-alcoholic-fatty-liver-disease-nafld-among-information-technology-it-professionals","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,7,26]],"date-time":"2025-07-26T06:47:34Z","timestamp":1753512454000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/383576-assessment-of-liver-enzymes-and-the-risk-of-non-alcoholic-fatty-liver-disease-nafld-among-information-technology-it-professionals"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,25]]},"references-count":30,"URL":"https:\/\/doi.org\/10.7759\/cureus.88786","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2025,7,25]]}}}